Biocon says it is well-placed to debut its partnered biosimilar to AbbVie’s Humira (adalimumab) in the US next year.
Biocon Claims Edge For Adalimumab In US
Cites Encouraging Payer Discussions Over Humira Biosimilar
Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.
